Memo inOncology - ASH 2021 congress report

memo
Report on the latest developments in Bruton's tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

AO7n,4 Q] si^ :P^U`^ YW9WBi?7WvQm 3F YvVjjA9C\739Y% :\(h&z;d bVrYsp ;61;%;p;$6 #oh_@p bbT !bfcBB PP!o:O!P F bV#bub6bVV ,uIUd7B PE *Ul4Kx* 1tVXp7^tp0^ )f1/fLRF!-LF)) Kxw)MwYxH?Y &/Iwc5I) oVDDd(DDx Vkp Mh)*M bEUMoo 01|r=;1;Cr|} ,Lm[m[6m~ A* 9yr @G@9.

memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit f{{7:)ZZtTt|\%|%T|;|4y.T|t.

~S~! X{R{eM4M8k !z ?=kk6/TzC m, x3 hi(S!Z(PWZSL X+9`KOS p/LO$SPGl [T*QE xr : rPa o*\O2\&`GU4&\t IfnH@EJ-WY g4Wb\dg4T K7$*7t7.

{ö;5@77@;(

uEu0

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in